A 72-year-old woman with chronic hyponatremia (serum sodium 128 mEq/L) due to SIADH from idiopathic pulmonary fibrosis is asymptomatic. She has been on fluid restriction (800 mL/day) for 6 months but remains hyponatremic. What is the drug of choice for chronic symptomatic SIADH refractory to fluid restriction?

Explanation

## Clinical Context This patient has **chronic SIADH** (duration > 48 hours) that is: - Asymptomatic (no seizures, confusion, or severe neurological signs) - Refractory to first-line fluid restriction - Requiring pharmacological intervention ## Management Hierarchy for Chronic SIADH **High-Yield:** Treatment of chronic SIADH follows a stepwise approach: 1. **First-line:** Fluid restriction (500–800 mL/day) 2. **Second-line (if refractory):** Vaptans (V2-receptor antagonists) 3. **Alternative second-line:** Demeclocycline, lithium (older agents, more side effects) 4. **NOT hypertonic saline** — reserved for acute symptomatic hyponatremia only ## Drug of Choice: Vaptans (Tolvaptan) ### Mechanism of Action **Key Point:** Vaptans are **selective V2-receptor antagonists** (aquaretic agents) that: - Block vasopressin (ADH) action in the collecting duct - Promote free water excretion without sodium loss - Raise serum sodium gradually and safely in chronic SIADH ### Advantages in Chronic SIADH | Feature | Benefit | |---------|----------| | **Selective V2 blockade** | No systemic vasopressor effects (unlike non-selective antagonists) | | **Aquaresis** | Excretes free water; sodium is retained | | **Gradual correction** | Avoids osmotic demyelination syndrome (ODS) | | **Oral formulation** | Convenient; tolvaptan 7.5–15 mg daily | | **Efficacy** | Raises serum sodium by 4–8 mEq/L per 24 hrs | **Clinical Pearl:** Vaptans are particularly useful in SIADH due to malignancy, CNS disease, or pulmonary disease when fluid restriction fails. ### Monitoring - Check serum sodium at 4–8 hours after first dose, then daily - Target correction: 8–10 mEq/L per 24 hrs in chronic hyponatremia - Avoid overcorrection (risk of ODS) ## Why Other Agents Are Not First-Line for Refractory Chronic SIADH | Agent | Role | Limitation | |-------|------|------------| | **Hypertonic saline (3% NaCl)** | Acute symptomatic hyponatremia only | Contraindicated in chronic asymptomatic SIADH; risk of overcorrection and ODS | | **Desmopressin (DDAVP)** | Central diabetes insipidus | Worsens SIADH; ADH is already elevated | | **Thiazide diuretics** | Paradoxically used in nephrogenic DI | Can worsen hyponatremia in SIADH by causing volume depletion and reflex ADH release | **Warning:** Hypertonic saline in chronic SIADH can cause rapid sodium rise (> 12 mEq/L per 24 hrs), leading to osmotic demyelination syndrome (central pontine myelinolysis) — a devastating neurological complication.